Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Viremia D014766 4 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Bronchiectasis D001987 7 associated lipids
Anthrax D000881 1 associated lipids
Heart Injuries D006335 6 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Neurologic Manifestations D009461 1 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Peyman JA et al. HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. 1992 Transplant. Proc. pmid:1533073
Kecskemeti V and Balogh I Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. 1995 Transplant. Proc. pmid:7482928
Yin M et al. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7482939
Spiegel HU et al. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. 1995 Transplant. Proc. pmid:7482955
Iwamoto H et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. 2000 Transplant. Proc. pmid:11119873
Bergmann R et al. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. 1990 Transplant. Proc. pmid:2389511
Immunomodulation: other approaches. 1988 Transplant. Proc. pmid:3347955
Renkonen R et al. Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. 1991 Transplant. Proc. pmid:1846709
Pignol B et al. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. 1988 Transplant. Proc. pmid:3259039
Chávez-Cartaya RE et al. Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes. 1994 Transplantation pmid:8197604
Foegh ML et al. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. 1986 Transplantation pmid:3523888
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Lanese DM et al. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. 1994 Transplantation pmid:7809931
dos Santos OF et al. Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation. 1989 Transplantation pmid:2705209
Gu M et al. Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors. 2000 Transplantation pmid:11045637
Saumweber DM et al. Hyperacute rejection in an ex vivo model of renal xenografting. Role of the mediator response and its pharmacologic manipulation by the specific platelet-activating factor antagonist WEB 2086BS. 1994 Transplantation pmid:8108870
Camussi G et al. Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. 1987 Transplantation pmid:3299910
Nishiyama R et al. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. 1993 Transplantation pmid:8516812
Kawahara K et al. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. 1993 Transplantation pmid:8516834
Suzuki S et al. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. 2000 Transplantation pmid:10868624